Tafenoquine

CAS : 106635-80-7

Ref. 3D-GEA63580

Informations sur le produit

• Nom: Tafenoquine
• Synonymes: (R)-N3-(2,6-Dimethoxy-4-methyl-5-(3-trifluoromethyl)phenoxy)quinolin-8-yl)pentane-1,4-diamine, (RS)-N(sup 3)-(2,6-Dimethoxy-4-methyl-5-(3-trifluoro-methylphenoxy)quinolin-8-yl)pentane-1,4-diamine, 1,4-Pentanediamine, N4-(2,6-dimethoxy-4-methyl-5-(3-(trifluoromethyl)phenoxy)-8-quinolinyl)-, 1,4-Pentanediamine, N⁴-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]-8-quinolinyl]-, N(4)-(2,6-Dimethoxy-4-methyl-5-((3-trifluoromethyl)phenoxy)-8-quinolinyl)-1,4-pentanediamine, N⁴-[2,6-Dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]-8-quinolinyl]-1,4-pentanediamine, N~4~-{2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-yl}pentane-1,4-diamine, Sb 252263Aab, Tafenoquine [INN:BAN], Unii-262P8Gs9L9, Wr 238605
• CAS: 106635-80-7

Description

Tafenoquine is a drug that is used to treat malaria. It binds to the mitochondrial membrane potential and blocks the production of ATP, leading to cell death. Tafenoquine has been shown to inhibit mitochondrial oxidative phosphorylation by binding to cytochrome b, thereby decreasing the production of ATP. Tafenoquine also inhibits nuclear DNA polymerase activity and other enzymes, such as cytosolic Ca2+-ATPases, which are involved in parasite development. Tafenoquine can be used as an alternative treatment for malaria when primaquine fails due to its ability to penetrate red blood cells that have become resistant to primaquine. This drug has also been shown to have anti-leishmanial properties and may be useful in treating leishmaniasis.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 463.5 g/mol
• Formule: C₂₄H₂₈F₃N₃O₃
• Degré de pureté: Min. 95%